1 min read

ID: 741358

Short Link: https://gregory-ms.com/articles/741358/

Discovery Date: 22 July 2022, 05:02:21 UTC

Published Date: 2022-07-21 10:00:00

Source: PubMed

Link: https://pubmed.ncbi.nlm.nih.gov/35863299/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20220722010221&v=2.17.7

Manual Selection: true

Machine Learning Gaussian Naive Bayes Model: false

Abstract

Fingolimod, used to treat relapsing-remitting multiple sclerosis (RRMS), reduces motor deficits in mice with established experimental autoimmune encephalomyelitis (EAE). To better characterize the therapeutic effects of fingolimod, kinematic gait analysis was employed to precisely measure movements of a hindleg while EAE mice walked on a treadmill. Relative to the vehicle group, oral dosing with fingolimod, beginning after disease onset (1 mg/kg/day), increased hip heights and knee joint…

Noun Phrases in Title

  • Fingolimod
  • gait deficits
  • mice
  • experimental autoimmune encephalomyelitis
This is an independent project that runs on the good will of volunteers

You can help by spreading the word or by donating what you can to pay for the server costs.